For example, neoadjuvant combination therapy, which adopts targeted agents and chemotherapy, is recommended for human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers [5]. Here, ERBB2 is linked to triple-negative breast carcinoma.